MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/tp.0000000000005260

Медицинская библиотека · Transplantation · 2025

Phase 2, Randomized, Double-blind, Placebo-controlled Study of Fiztasovimab (NPC-21) for Kidney Transplant Recipients at High Risk of Cytomegalovirus Infection (LionHeart21).

Ichimaru Naotsugu, Natori Yoichiro, Alloway Rita R, Wojciechowski David, Castillo Almeida Natalia E, Futamura Kenta, Watanabe Tatsuya, Nakagawa Ken, Egawa Hiroto, LionHeart21 Study Group

СтатьяРандомизированное исследованиеКлиническое исследование II фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Kidney transplantation (KT) has dramatically improved the quality of life of patients with end-stage kidney disease. However, the incidence of opportunistic infections has also increased because of immunosuppression. A common infection after KT is cytomegalovirus (CMV). In KT recipients, we assessed the efficacy and safety of fiztasovimab (NPC-21), an anti-CMV monoclonal antibody.

METHODS

This was a multicenter, randomized, double-blind, placebo-controlled, phase 2 study of NPC-21 for KT recipients with CMV donor-positive (D + )/recipient-negative (R - ) serostatus. Patients were randomly assigned to receive monthly 6 or 12 mg/kg NPC-21, or placebo, in a 4:1:4 ratio. The primary efficacy endpoint was CMV infection by week 16.

RESULTS

Eighty-seven KT recipients were randomized; 38, 11, and 38 received 6 mg/kg of NPC-21, 12 mg/kg of NPC-21, or placebo, respectively. CMV infections occurred in 29 of 38 (76.3%), 9 of 11 (81.8%), and 26 of 38 (68.4%) patients in the 6 mg/kg NPC-21, 12 mg/kg NPC-21, and placebo groups, respectively, with no statistically significant differences. CMV disease occurred in 2 of 49 (4.1%) versus 5 of 38 (13.2%) patients in the 6 and 12 mg/kg combined NPC-21 group versus the placebo group. The absolute difference (95% confidence interval) was -9.1 (-23.9 to 2.8). No significant adverse events were observed after NPC-21 administration.

CONCLUSIONS

NPC-21 was safe, but no significant efficacy difference was found between NPC-21 and placebo. Severe CMV infection was less likely in the NPC-21 group versus the placebo group. Further studies are needed to elucidate the role of NPC-21 in the prevention of CMV.

Для цитирования: Ichimaru Naotsugu, Natori Yoichiro, Alloway Rita R, Wojciechowski David, Castillo Almeida Natalia E, Futamura Kenta, Watanabe Tatsuya, Nakagawa Ken, Egawa Hiroto, LionHeart21 Study Group. Phase 2, Randomized, Double-blind, Placebo-controlled Study of Fiztasovimab (NPC-21) for Kidney Transplant Recipients at High Risk of Cytomegalovirus Infection (LionHeart21).. Transplantation. 2025. DOI: 10.1097/tp.0000000000005260.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.